Yes. I think I was over-selling my point and that was a mistake. Our back and forth was useful and I’ll have to think about it again when I look at DPR again.
By way of explanation, I think I was venting my frustrationg at the ratio of “time I spend researching and writing about drug policy reform:serious interest it received”
For what it’s worth, we had some back & forth regarding modeling assumptions around drug policy reform cost-effectiveness:
http://effective-altruism.com/ea/1em/costeffectiveness_analysis_drug_liberalization/bx1
I remember. I don’t think we quite got the bottom of the issue however and couldn’t agree what the right counterfactual was.
Sure, but I don’t think the right summary here is “no one has told me how my EV calc is wrong.”
A better summary probably includes something like “EV calcs are complicated and their outputs are very sensitive to the modeling assumptions used.”
Yes. I think I was over-selling my point and that was a mistake. Our back and forth was useful and I’ll have to think about it again when I look at DPR again.
By way of explanation, I think I was venting my frustrationg at the ratio of “time I spend researching and writing about drug policy reform:serious interest it received”